Topaz Investment

Topas Therapeutics is a clinical-stage German biotechnology company specializing in the development of antigen-specific tolerance induction therapies for autoimmune diseases, allergies, and drug-related immune reactions. The company's proprietary Topas Particle Technology (TPT) platform utilizes liver-targeting nanoparticles to deliver specific antigens to liver sinusoidal endothelial cells (LSECs), mimicking the natural process of immune tolerance induction. Their lead clinical program, TPM502, is currently in Phase 2 development for celiac disease, aiming to restore immune tolerance to gluten. By targeting the liver's natural ability to regulate the immune system, Topas seeks to provide long-term disease modification without the need for broad immunosuppression.